The third committee meeting of the ninth Pharmacopoeia Committee was held

On February 1, the third committee meeting of the ninth Pharmacopoeia Committee and the summary meeting of the preparation of 2010 edition of Chinese Pharmacopoeia were held in Beijing Shao Mingli, director of the State Food and Drug Administration and chairman of the ninth Pharmacopoeia Committee, attended the meeting and delivered a speech The 2010 edition of Chinese pharmacopoeia is the ninth edition of Pharmacopoeia since the founding of the people's Republic of China This edition of Pharmacopoeia has a total of 4567 varieties, including 1386 new varieties; Pharmacopoeia I has a total of 2165 new varieties, including 1019 new ones and 634 revised ones; Pharmacopoeia II has a total of chemical drugs, antibiotics, biochemical drugs and radioactive drugs There are 2271 products and pharmaceutical accessories in total, including 330 new ones and 1500 revised ones; 131 varieties of biological products are collected in the third part of Pharmacopoeia, including 37 new ones and 94 revised ones; 47 new ones and 154 revised ones in the appendix of Pharmacopoeia The successful completion of the preparation of 2010 edition of Chinese Pharmacopoeia marks that the national action plan for improving drug standards has achieved important stage results, which is of great significance to ensure public drug safety and promote the healthy development of China's medical and health undertakings Shao Mingli fully affirmed the achievements of the preparation of 2010 edition of Chinese Pharmacopoeia under the close cooperation, careful arrangement and efforts of the ninth Pharmacopoeia Committee and its standing body, the general Pharmacopoeia Committee, and the drafting and review units of drug standards, deeply explained the important position of the current drug standard work, as well as the historical opportunities and challenges faced It is hoped that all pharmaceutical standard workers will take 2010 edition of China Pharmacopoeia as a new starting point of pharmaceutical standard work, seriously consider the development direction of national pharmaceutical standard work under the new situation, further do a good job in the preparation and revision of China Pharmacopoeia and national pharmaceutical standard, and realize the new development of national pharmaceutical standard work: first, establish and improve the system of pharmaceutical standard laws and regulations Carefully sort out the provisions of the drug administration law and the implementing regulations, laws and regulations of the drug administration law, deeply analyze the problems existing in the work of national drug standards, deeply consider the functional orientation and development direction of the national pharmacopoeia committee, sort out the mechanism of drug standards work from the source, clarify the responsibilities of relevant organizations in the work of drug standards, and institutionalize and standardize the work of drug standards Provide legal protection Second, we should constantly improve the overall level of national drug standards We should seize the opportunity to implement the national essential drug system and accelerate the implementation of the national action plan for improving drug standards In the near future, we should focus on the improvement of drug standards for high-risk varieties such as national essential drug catalogue, injections, vaccines, and several kinds of products such as traditional Chinese medicine and ethnic medicine Third, we should continue to optimize the management mechanism of drug standards It is necessary to comprehensively summarize the experience of the preparation of the Chinese pharmacopoeia in the previous stage, analyze the shortcomings in the management of drug standards, continuously optimize and improve the management mechanism of drug standards, practically strengthen the certification and assessment of the qualifications of institutions undertaking the scientific research tasks of the Chinese Pharmacopoeia, and establish an effective scientific management system Fourth, we should actively plan the preparation of the 2015 edition of the Chinese Pharmacopoeia We should put the compilation of the 2015 edition of the Chinese Pharmacopoeia on the agenda, make scientific arrangements and actively promote it It is necessary to work out the working outline of 2015 edition of Chinese Pharmacopoeia, prepare the scientific research plan and arrange the basic research in advance Fifth, we should speed up the construction of a high-quality and compound talent team It is necessary to strengthen the team building of Pharmacopoeia Committee members, establish incentive mechanism, support the Pharmacopoeia Committee members to carry out in-depth basic research, actively participate in international standardization activities, and constantly innovate the quality control research of traditional Chinese medicine; it is necessary to strengthen the training of young experts, cultivate a group of young backbone forces who are proficient in business, familiar with laws and regulations, and have strong international communication ability; it is necessary to care about the permanent organization of Pharmacopoeia Committee To build a better platform and provide more support for the development of this team Wu Zhen, deputy director of the State Food and Drug Administration and Secretary General of the national pharmacopoeia committee, presided over the meeting and read out the decision on Commending 21 Pharmacopoeia members including Xiao Peigen Bian Zhenjia, deputy director of the State Food and drug administration, Yu Wenming, deputy director of the State Administration of traditional Chinese medicine, and relevant responsible comrades from ministries and commissions such as the Ministry of health, the state people's Committee, the Ministry of science and technology, and the Ministry of health after the general manager attended the meeting.